Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals . Brazilian Journal of Pharmaceutical Sciences, [S. l.], v. 47, n. 1, p. 31–38, 2011. DOI: 10.1590/S1984-82502011000100005. Disponível em: https://revistas.usp.br/bjps/article/view/10853.. Acesso em: 12 may. 2024.